Revolution Medicines Inc
RVMD40.590USD
-0.519-1.26%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
7.56BMarket Cap
LossP/E TTM
More Details of Revolution Medicines Inc Company
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
Ticker SymbolRVMD
Company nameRevolution Medicines Inc
IPO dateFeb 13, 2020
Founded at2014
CEODr. Mark A. Goldsmith, M.D., Ph.D.
Number of employees534
Security typeOrdinary Share
Fiscal year-endFeb 13
Address700 Saginaw Dr
CityREDWOOD CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94063-4752
Phone14157663638
Websitehttps://www.revmed.com/
Ticker SymbolRVMD
IPO dateFeb 13, 2020
Founded at2014
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
89.61K
+30.23%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
64.48K
+99.46%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
63.95K
+9.09%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
54.86K
+57.01%
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
Dr. Flavia Borellini, Ph.D.
Dr. Flavia Borellini, Ph.D.
Independent Director
Independent Director
17.63K
+18.56%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Independent Director
Independent Director
13.95K
+61.78%
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
Independent Director
Independent Director
8.82K
+12.10%
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
89.61K
+30.23%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
64.48K
+99.46%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
63.95K
+9.09%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
54.86K
+57.01%
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.90%
Farallon Capital Management, L.L.C.
7.27%
BlackRock Institutional Trust Company, N.A.
6.86%
Wellington Management Company, LLP
6.33%
Janus Henderson Investors
5.47%
Other
65.17%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.90%
Farallon Capital Management, L.L.C.
7.27%
BlackRock Institutional Trust Company, N.A.
6.86%
Wellington Management Company, LLP
6.33%
Janus Henderson Investors
5.47%
Other
65.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.36%
Investment Advisor
33.04%
Hedge Fund
29.21%
Venture Capital
4.71%
Research Firm
2.55%
Individual Investor
2.02%
Sovereign Wealth Fund
0.94%
Bank and Trust
0.54%
Private Equity
0.54%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
556
204.75M
109.97%
+13.10M
2024Q4
550
200.50M
107.86%
+9.16M
2024Q3
508
178.03M
106.09%
-11.19M
2024Q2
474
175.13M
105.71%
-4.08M
2024Q1
450
165.87M
97.52%
-10.22M
2023Q4
413
166.29M
101.77%
+33.45M
2023Q3
369
116.05M
106.21%
-8.60M
2023Q2
358
115.90M
109.17%
-5.53M
2023Q1
356
111.78M
105.38%
+16.81M
2022Q4
350
91.36M
103.00%
-6.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
17.07M
9.18%
+2.18M
+14.67%
Dec 31, 2024
Farallon Capital Management, L.L.C.
13.25M
7.13%
+1.93M
+17.06%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
12.63M
6.8%
+1.08M
+9.32%
Dec 31, 2024
Wellington Management Company, LLP
10.82M
5.82%
-579.70K
-5.08%
Dec 31, 2024
Janus Henderson Investors
9.48M
5.1%
+3.35M
+54.53%
Dec 31, 2024
Baker Bros. Advisors LP
7.94M
4.27%
+367.88K
+4.86%
Dec 31, 2024
Nextech Invest, Ltd.
7.60M
4.09%
+1.30M
+20.71%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.53M
3.51%
+653.68K
+11.13%
Dec 31, 2024
Paradigm BioCapital Advisors LP
6.55M
3.52%
+1.24M
+23.32%
Dec 31, 2024
State Street Global Advisors (US)
5.79M
3.12%
+512.17K
+9.70%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Tema Oncology ETF
6.1%
iShares Genomics Immunology and Healthcare ETF
3.92%
SPDR S&P Biotech ETF
1.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.95%
Invesco Nasdaq Biotechnology ETF
0.77%
Harbor Health Care ETF
0.74%
ProShares Ultra Nasdaq Biotechnology
0.72%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
iShares Biotechnology ETF
0.61%
JPMorgan Healthcare Leaders ETF
0.55%
View more
Tema Oncology ETF
Proportion6.1%
iShares Genomics Immunology and Healthcare ETF
Proportion3.92%
SPDR S&P Biotech ETF
Proportion1.45%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.95%
Invesco Nasdaq Biotechnology ETF
Proportion0.77%
Harbor Health Care ETF
Proportion0.74%
ProShares Ultra Nasdaq Biotechnology
Proportion0.72%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.65%
iShares Biotechnology ETF
Proportion0.61%
JPMorgan Healthcare Leaders ETF
Proportion0.55%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
